AbbVie Inc. disappointed investors this weekend with the presentation of Phase Ia/Ib trial for a small cell lung cancer treatment. While the data showed some encouraging results in a subset of patients with high delta-like protein-3 (DLL3) expression, overall data was not as robust as investors hoped.
The company's stock dropped more than 5% in early-morning trading, but rebounded slightly to end the day down. At the...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)